港股君实生物拉升，一度涨超30%。 ...

每经AI快讯，8月5日，港股君实生物拉升，一度涨超30%，现涨24%。 （文章来源：每日经济新闻） ...

Group 1 - The core viewpoint highlights the strong performance and growth of the Kexin Pharmaceutical ETF managed by Jiashi, with significant trading activity and inflows [2] - As of August 4, the Kexin Pharmaceutical ETF Jiashi has seen a weekly average trading volume of 58.54 million yuan, ranking first among comparable funds [2] - The fund's scale increased by 12.30 million yuan over the past two weeks, also leading among comparable funds [2] - The fund's net asset value has risen by 50.01% over the past year, placing it in the top 15.64% of index equity funds [2] Group 2 - The top ten weighted stocks in the Shanghai Stock Exchange Science and Technology Innovation Board Biopharmaceutical Index account for 49.14% of the index, with leading companies including United Imaging Healthcare and BeiGene [2][4] - The biopharmaceutical industry is expected to stabilize and grow throughout 2025, supported by favorable policies for innovative drug development and medical equipment updates [5] - The transition to the 2.0 era of innovative drugs in China is marked by a qualitative improvement, with domestic new drugs expected to participate deeply in the global market over the next decade [4]

本文源自：金融界 作者：智投君 8月4日，沪深两融数据显示，君实生物获融资买入额0.58亿元，居两市第285位，当日融资偿还额0.65亿 元，净卖出716.91万元。 最近三个交易日，31日-4日，君实生物分别获融资买入0.70亿元、0.68亿元、0.58亿元。 融券方面，当日融券卖出0.58万股，净卖出0.46万股。 ...

Group 1: Robotics and Automation - Tianzhun Technology has developed an intelligent driving domain controller that can serve the Robotaxi sector [1] - Haoshi Electromechanical has successfully applied a massage robot in professional beauty chain institutions [1] - Xinhongye is focusing on the research and development of humanoid robot cable technology and product iteration [1] Group 2: Semiconductor and Related Technologies - Huagong Technology's self-developed 1.6T silicon optical module has entered the sample testing phase with key customers [2] - Longtu Photomask is providing semiconductor masks for Innosilicon [2] - Yangjie Technology has released new products applicable to AR glasses and related fields [2] Group 3: Other Industry Developments - Rongda Photosensitive is supplying PCB photoresist products to Shenghong Technology [1] - Deyuan Pump Industry has products compatible with fluorine pump natural cooling systems [2] - Zhongyuan Tong's power products are core components of liquid-cooled server equipment [2] - China Chemical is engaging in business connections with owners related to the Yarlung Tsangpo River downstream project [2] - Grinmei's ultra-high nickel 9-series ternary precursor has passed mass production certification and achieved small-scale production of ten tons [2]

君实生物（688180.SH）8月4日在投资者互动平台表示，截至本回复日，公司尚无抗生素相关业务。 每经AI快讯，有投资者在投资者互动平台提问：贵公司是否涉及抗生素相关业务？如果是，为何未见 在年报和ESG报告中披露抗生素管理相关信息，后续是否有计划在年报及ESG报告中披露具体的抗生素 管理风险与机遇？ （文章来源：每日经济新闻） ...

作者：公告君 公司回答表示：投资人您好，截至本回复日，公司尚无抗生素相关业务。谢谢您的关注。 本文源自：金融界 金融界8月4日消息，有投资者在互动平台向君实生物提问：贵公司是否涉及抗生素相关业务？如果是， 为何未见在年报和ESG报告中披露抗生素管理相关信息，后续是否有计划在年报及ESG报告中披露具体 的抗生素管理风险与机遇？ ...

格隆汇8月4日丨君实生物(688180.SH)在互动平台表示，截至本回复日，公司尚无抗生素相关业务。 ...

中国经济网北京8月4日讯 君实生物(688180.SH)今日股价下跌，截至收盘报37.66元，跌幅1.10%。该股 目前处于破发状态。 君实生物于2020年7月15日在上交所科创板上市，发行数量为8713万股，发行价格为55.50元/股，保荐 机构、主承销商为中国国际金融股份有限公司，联席主承销商为国泰君安证券股份有限公司、海通证券 股份有限公司(2家公司现已合并为国泰海通证券股份有限公司)。 上市首日，君实生物股价最高报220.40元，此后该股一路震荡下滑。该股目前处于破发状态。 君实生物首次公开发行股票募集资金总额为48.36亿元，扣除发行费用后，募集资金净额为44.97亿元， 较原计划多17.97亿元。君实生物于2020年7月8日发布的招股说明书显示，该公司计划募集资金27.00亿 元，分别用于创新药研发项目、君实生物科技产业化临港项目、偿还银行贷款及补充流动资金。 君实生物首次公开发行股票募的发行费用为3.39亿元，其中，保荐及承销费用3.20亿元。 君实生物2022年度向特定对象发行A股股票募集资金情况为，根据中国证监会出具的《关于同意上海君 实生物医药科技股份有限公司向特定对象发行股票注册的批复》 ...

Core Viewpoint - Junshi Biosciences aims to establish itself as a global innovative pharmaceutical company with a complete industry chain capability from drug discovery to commercialization, focusing on quality and innovation [2][3]. Company Overview - Junshi Biosciences was founded on December 27, 2012, and listed on July 15, 2020. The company specializes in the research and commercialization of monoclonal antibody drugs and other therapeutic protein drugs [7]. - The main revenue sources include 84.18% from drug sales, 12.08% from technology licensing, and 3.73% from other sources [7]. Product Development - The company has developed a significant product portfolio, including the first domestically approved PD-1 monoclonal antibody, Toripalimab, which has received approval for 11 indications in mainland China and is also approved in multiple countries including the US and EU [2]. - Junshi's Tifcemalimab is the first anti-tumor BTLA monoclonal antibody to enter clinical development, with ongoing Phase III trials and several combination studies with Toripalimab [2]. Recent Collaborations - On October 27, 2023, Junshi announced collaborations with several institutions, including Peking University and the Chinese Academy of Sciences, to develop a monkeypox recombinant protein vaccine [3]. Financial Performance - For the first quarter of 2025, Junshi reported revenue of 5.01 billion yuan, a year-on-year increase of 31.46%, while the net profit attributable to shareholders was -235 million yuan, reflecting a 17.01% year-on-year growth [8]. Market Position - As of March 31, 2025, Junshi had 29,400 shareholders, with an average of 25,987 circulating shares per person, indicating a slight decrease in share distribution [8]. - The company operates within the pharmaceutical and biotechnology sector, focusing on innovative drugs and biopharmaceuticals [8].